A.R.T. Advisors LLC reduced its stake in shares of Cerus Co. (NASDAQ:CERS) by 57.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 88,281 shares of the biotechnology company’s stock after selling 118,200 shares during the period. A.R.T. Advisors LLC owned approximately 0.07% of Cerus worth $483,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of CERS. Jump Trading LLC acquired a new position in Cerus during the first quarter valued at $104,000. Teacher Retirement System of Texas acquired a new position in Cerus during the fourth quarter valued at $126,000. MetLife Investment Advisors LLC acquired a new position in Cerus during the fourth quarter valued at $197,000. Alambic Investment Management L.P. acquired a new position in Cerus during the first quarter valued at $225,000. Finally, Two Sigma Investments LP acquired a new position in Cerus during the fourth quarter valued at $249,000. Institutional investors and hedge funds own 60.09% of the company’s stock.

A number of research analysts recently issued reports on CERS shares. BidaskClub upgraded shares of Cerus from a “hold” rating to a “buy” rating in a research report on Tuesday, March 6th. Zacks Investment Research upgraded shares of Cerus from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a research report on Tuesday, April 10th. ValuEngine upgraded shares of Cerus from a “hold” rating to a “buy” rating in a research report on Friday, May 4th. Finally, BTIG Research restated a “hold” rating on shares of Cerus in a research report on Saturday, March 10th. Two investment analysts have rated the stock with a hold rating, three have given a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $5.44.

In other Cerus news, CFO Kevin Dennis Green sold 73,000 shares of the company’s stock in a transaction dated Thursday, May 17th. The shares were sold at an average price of $6.42, for a total value of $468,660.00. Following the completion of the transaction, the chief financial officer now owns 83,825 shares in the company, valued at $538,156.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Carol Moore sold 75,000 shares of the company’s stock in a transaction dated Tuesday, June 5th. The stock was sold at an average price of $6.72, for a total transaction of $504,000.00. Following the completion of the transaction, the senior vice president now owns 46,363 shares of the company’s stock, valued at approximately $311,559.36. The disclosure for this sale can be found here. In the last quarter, insiders sold 292,972 shares of company stock valued at $1,913,341. Insiders own 6.80% of the company’s stock.

Shares of Cerus stock opened at $6.91 on Wednesday. The stock has a market capitalization of $870.73 million, a price-to-earnings ratio of -12.29 and a beta of 1.75. Cerus Co. has a fifty-two week low of $2.10 and a fifty-two week high of $7.31. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.66 and a quick ratio of 5.10.

Cerus (NASDAQ:CERS) last issued its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. The business had revenue of $13.56 million during the quarter, compared to the consensus estimate of $12.22 million. Cerus had a negative net margin of 111.46% and a negative return on equity of 111.19%. The company’s revenue was up 93.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.18) earnings per share. sell-side analysts predict that Cerus Co. will post -0.45 earnings per share for the current year.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.

Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Co. (NASDAQ:CERS).

Institutional Ownership by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.